By studying the effects of the nasal anti-CD3 in a ... Multiple Sclerosis: Cell-Catching Implant Helps Identify Successful Treatment in Mice Feb. 18, 2025 — A sponge-like implant in mice helped ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib ...

Researchers from the Netherlands Institute for Neuroscience (NIN) have discovered new potential therapeutic targets for multiple sclerosis (MS). While current treatments prevent further damage ...

A new study published in Multiple Sclerosis and Related Disorders highlights the potential of "More Stamina," a gamified mobile health (mHealth) app designed to help people with multiple sclerosis ...

Depression and anxiety have been well documented in people with multiple sclerosis (MS), but often are undiagnosed or untreated. A machine learning model may help by analyzing routinely collected ...

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed. A new artificial ...

SAVANNAH, Ga. (WTOC) - March is Multiple Sclerosis awareness month. It’s an autoimmune disease that impacts nearly a million people around the world. This month, our Jasmine Butler is bringing us ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.

Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...

Christina Applegate got emotional opening up about her struggle with multiple sclerosis, nearly four years after she was first diagnosed. “I am defined by it right now,” the actor said during ...

More data are needed on its efficacy and safety in treating relapsing multiple sclerosis. In two phase 3, double-blind, double-dummy, event-driven trials (GEMINI 1 and GEMINI 2), participants with ...